<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05059873</url>
  </required_header>
  <id_info>
    <org_study_id>Z201100005520029</org_study_id>
    <nct_id>NCT05059873</nct_id>
  </id_info>
  <brief_title>Treatment Efficacy of Systemic Corticosteroids in AECOPD Patients With Higher Blood Eosinophil Levels</brief_title>
  <official_title>A Multicenter Double-blind Randomized Controlled Trial of Systemic Corticosteroid Therapy in AECOPD Patients Admitted to Hospital With Higher Blood Eosinophil Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Tongren Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Luhe Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emergency General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Jishuitan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Jingmei Group Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Shijingshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bejing INFI-SAGACITY TECHNOLOGY CO., LTD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic Obstructive Pulmonary Disease (COPD) is one of the top three causes of death&#xD;
      worldwide now. Acute exacerbations (AEs) of COPD are a risk factor for lung function&#xD;
      deterioration, poor quality of life, longer hospitalization, and increased mortality. To&#xD;
      date, COPD is associated with a heavy clinical and socioeconomic burden, of which AEs of COPD&#xD;
      account for a significant part of the cost of patients with COPD. Although several&#xD;
      retrospective cohort studies and post-hoc analyses from randomized controlled trials (RCTs)&#xD;
      showed that AECOPD patients with higher blood eosinophils had a shorter length of hospital&#xD;
      stay (LOS), lower doses of corticosteroid use, and better response to systematic&#xD;
      corticosteroid treatment than those with lower blood eosinophils, the efficacy of systematic&#xD;
      corticosteroids in AECOPD patients with higher blood eosinophils has not been confirmed by&#xD;
      RCTs. Therefore, this study aims to evaluate if AECOPD patients admitted to hospitals with&#xD;
      higher blood eosinophil levels could benefit from systemic corticosteroid therapy. In this&#xD;
      study, all eligible AECOPD participants with peripheral blood eosinophil blood count &gt; 150ul&#xD;
      will be randomly assigned (1:1) to either a control group or a systemic corticosteroid group.&#xD;
      The control group will receive an oral placebo of 40mg/day for five consecutive days in&#xD;
      addition to standard treatment during emergency admission or hospitalization. And systemic&#xD;
      corticosteroid group will receive oral prednisone 40mg/day for five consecutive days and&#xD;
      standard treatment. This study will provide evidence on using absolute peripheral blood&#xD;
      eosinophil blood count to guide corticosteroid therapy in AECOPD patients and help the&#xD;
      clinician make an individual decision for each patient.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 10, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment failure rates</measure>
    <time_frame>30 days</time_frame>
    <description>Collect during index hospitalization and within 30 days after discharge.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Admission to ICU rates during index hospitalization</measure>
    <time_frame>14 days</time_frame>
    <description>Collect during index hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requiring or receiving invasive or non-invasive MV rates during index hospitalization</measure>
    <time_frame>14 days</time_frame>
    <description>Collect during index hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality during index hospitalization and within 90 days after discharge</measure>
    <time_frame>90 days</time_frame>
    <description>Collect during index hospitalization and 90-day follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The length of hospital stay during index hospitalization</measure>
    <time_frame>14 days</time_frame>
    <description>Collect during index hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission rates of AECOPD at 30-day, 60-day, and 90-day follow-ups</measure>
    <time_frame>90 days</time_frame>
    <description>Collect during 90-day follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to readmission of AECOPD within 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>Collect during 90-day follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in FEV1 between index hospitalization and 90-day follow-up</measure>
    <time_frame>90 days</time_frame>
    <description>Collect during 90-day follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the scores of EXAcerbations of Chronic pulmonary disease Tool between index hospitalization and 90-day follow-up</measure>
    <time_frame>90 days</time_frame>
    <description>Collect during 90-day follow-up. The minimum and maximum values are 0 and 100, respectively. Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the scores of St. George's Respiratory Questionnaire between index hospitalization and 90-day follow-up</measure>
    <time_frame>90 days</time_frame>
    <description>Collect during 90-day follow-up. The minimum and maximum values are 1 and 80, respectively. Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the scores of Hospital Anxiety and Depression Scale between index hospitalization and 90-day follow-up</measure>
    <time_frame>90 days</time_frame>
    <description>Collect during 90-day follow-up. The minimum and maximum values are 0 and 42, respectively. Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">456</enrollment>
  <condition>Acute Exacerbation of COPD</condition>
  <condition>Corticosteroid</condition>
  <condition>Morality</condition>
  <condition>Lung Diseases, Obstructive</condition>
  <condition>Blood Eosinophil Count</condition>
  <condition>COPD</condition>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Systemic corticosteroid group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Oral prednisone 40mg/day for five consecutive days in addition to standard treatment during emergency admission or hospitalization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participating patients will receive an oral placebo of 40mg/day for five consecutive days in addition to standard treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Oral prednisone 40mg/day for five consecutive days</description>
    <arm_group_label>Systemic corticosteroid group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral placebo of 40mg/day for five consecutive days</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Aged between 40 and 80 years old;&#xD;
&#xD;
          -  2. Current or former cigarette smokers (≥10 packs per year);&#xD;
&#xD;
          -  3. Spirometry-verified COPD (defined as postbronchodilator forced expiratory volume in&#xD;
             the first second (FEV1)/ forced vital capacity (FVC) ≤ 0.70);&#xD;
&#xD;
          -  4. Within 72 hours of emergency admission or within 24 hours of hospitalization;&#xD;
&#xD;
          -  5. The initial absolute peripheral eosinophil count &gt;150ul/L which was tested within&#xD;
             72 hours of emergency admission or 24 hours within hospitalization;&#xD;
&#xD;
          -  6. Current AECOPD meet the definition of AECOPD according to the Global Initiative for&#xD;
             Chronic Obstructive Lung Disease (GOLD) guideline;&#xD;
&#xD;
          -  7. Written informed consent before inclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Admission due to other diseases (pneumonia, pneumothorax, ect);&#xD;
&#xD;
          -  2. Participating in or completed another drug trial within 90 days;&#xD;
&#xD;
          -  3. Pregnancy or lactation;&#xD;
&#xD;
          -  4. Require invasive mechanical ventilation (IMV) or transfer to intensive care unit&#xD;
             (ICU) within 24 hours after emergency admission or hospitalization;&#xD;
&#xD;
          -  5. With complications that may cause eosinophilia;&#xD;
&#xD;
          -  6. With pulmonary embolism in the past two years before emergency admission or&#xD;
             hospitalization;&#xD;
&#xD;
          -  7. With myocardial infarction in the past four weeks before emergency admission or&#xD;
             hospitalization, uncontrollable congestive heart failure or arrhythmia;&#xD;
&#xD;
          -  8. With comorbidity that may influence the immune system;&#xD;
&#xD;
          -  9. With neuromuscular disease affecting the respiratory system;&#xD;
&#xD;
          -  10. Pulmonary interstitial disease or active tuberculosis or bronchiectasis;&#xD;
&#xD;
          -  11. Systemic fungal infection;&#xD;
&#xD;
          -  12. Previous lung surgery, including thoracotomy or bronchoscopic lung volume&#xD;
             reduction surgery;&#xD;
&#xD;
          -  13. Received prednisone ≥ 60mg in the past three days before emergency admission or&#xD;
             hospitalization (or equivalent doses of other corticosteroid)；&#xD;
&#xD;
          -  14. Allergic or intolerant to corticosteroid;&#xD;
&#xD;
          -  15. Uncontrollable severe psychiatric illnesses even with medication, cognitive&#xD;
             impairment, and severe language difficulties;&#xD;
&#xD;
          -  16. Life expectancy less than three months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tong Zhaohui, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Chao Yang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rong Hengmo, PhD</last_name>
    <phone>+8615810271669</phone>
    <email>ronghengmo@sina.com</email>
  </overall_contact>
  <link>
    <url>http://rs.yiigle.com/CN131368201714/1000344.htm</url>
    <description>Chinese expert consensus on the diagnosis and treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) (updated version in 2017)</description>
  </link>
  <reference>
    <citation>Labaki WW, Rosenberg SR. Chronic Obstructive Pulmonary Disease. Ann Intern Med. 2020 Aug 4;173(3):ITC17-ITC32. doi: 10.7326/AITC202008040. Review.</citation>
    <PMID>32745458</PMID>
  </reference>
  <reference>
    <citation>Duffy SP, Criner GJ. Chronic Obstructive Pulmonary Disease: Evaluation and Management. Med Clin North Am. 2019 May;103(3):453-461. doi: 10.1016/j.mcna.2018.12.005. Epub 2019 Mar 14. Review.</citation>
    <PMID>30955513</PMID>
  </reference>
  <reference>
    <citation>Sivapalan P, Lapperre TS, Janner J, Laub RR, Moberg M, Bech CS, Eklöf J, Holm FS, Armbruster K, Sivapalan P, Mosbech C, Ali AKM, Seersholm N, Wilcke JT, Brøndum E, Sonne TP, Rønholt F, Andreassen HF, Ulrik CS, Vestbo J, Jensen JS. Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. Lancet Respir Med. 2019 Aug;7(8):699-709. doi: 10.1016/S2213-2600(19)30176-6. Epub 2019 May 20.</citation>
    <PMID>31122894</PMID>
  </reference>
  <reference>
    <citation>Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1418-22.</citation>
    <PMID>9603117</PMID>
  </reference>
  <reference>
    <citation>Wedzicha JA, Singh R, Mackay AJ. Acute COPD exacerbations. Clin Chest Med. 2014 Mar;35(1):157-63. doi: 10.1016/j.ccm.2013.11.001. Review.</citation>
    <PMID>24507843</PMID>
  </reference>
  <reference>
    <citation>Bafadhel M, Greening NJ, Harvey-Dunstan TC, Williams JE, Morgan MD, Brightling CE, Hussain SF, Pavord ID, Singh SJ, Steiner MC. Blood Eosinophils and Outcomes in Severe Hospitalized Exacerbations of COPD. Chest. 2016 Aug;150(2):320-8. doi: 10.1016/j.chest.2016.01.026. Epub 2016 Feb 3.</citation>
    <PMID>26851799</PMID>
  </reference>
  <reference>
    <citation>Cui Y, Zhan Z, Zeng Z, Huang K, Liang C, Mao X, Zhang Y, Ren X, Yang T, Chen Y. Blood Eosinophils and Clinical Outcomes in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Propensity Score Matching Analysis of Real-World Data in China. Front Med (Lausanne). 2021 Jun 9;8:653777. doi: 10.3389/fmed.2021.653777. eCollection 2021.</citation>
    <PMID>34179040</PMID>
  </reference>
  <reference>
    <citation>Ko FWS, Chan KP, Ngai J, Ng SS, Yip WH, Ip A, Chan TO, Hui DSC. Blood eosinophil count as a predictor of hospital length of stay in COPD exacerbations. Respirology. 2020 Mar;25(3):259-266. doi: 10.1111/resp.13660. Epub 2019 Aug 6.</citation>
    <PMID>31385389</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 18, 2021</study_first_submitted>
  <study_first_submitted_qc>September 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Zhaohui Tong</investigator_full_name>
    <investigator_title>Derictor of Beijing Institute of Respiratory Medicine and Vice president of Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China</investigator_title>
  </responsible_party>
  <keyword>Treatment failure rates</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Mortality</keyword>
  <keyword>Corticosteroid</keyword>
  <keyword>Acute Exacerbation of Chronic Obstructive Pulmonary Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

